Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 9.3% – Time to Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares fell 9.3% on Monday . The stock traded as low as $0.25 and last traded at $0.25. 26,384,189 shares were traded during mid-day trading, a decline of 60% from the average session volume of 66,618,578 shares. The stock had previously closed at $0.28.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a report on Thursday, January 9th. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Trading Down 4.0 %

The firm has a fifty day moving average of $0.25 and a two-hundred day moving average of $0.31. The company has a market cap of $40.74 million, a PE ratio of 0.00 and a beta of 2.02. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. The business had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, sell-side analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.